ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

U.S. Generics Shuffle

by Rick Mullin
September 14, 2015 | APPEARED IN VOLUME 93, ISSUE 36

The Belgian drugmaker UCB will sell its U.S. generics business, Kremers Urban Pharmaceuticals, to Philadelphia-based Lannett for $1.2 billion. Under the deal, UCB is eligible to receive payments for methylphenidate HCl Extended Release, a generic version of Janssen’s central nervous system drug Concerta, in the event that the product’s bioequivalence rating is restored. Kremers won FDA approval in 2013, but last year FDA requested data to confirm its therapeutic equivalence to Concerta. Lannett says the purchase will roughly double its annual sales to $800 million, add a strong R&D team, and bring the potential for advancing its active pharmaceutical ingredients business. Meanwhile, the Indian drug firm Cipla will acquire the U.S. generic drug maker InvaGen Pharmaceuticals and Exelan Pharmaceuticals, a marketing firm that sells InvaGen products to government buyers, in a deal valued at $550 million. InvaGen has 32 marketed products and about 40 applications pending FDA approval. It operates a plant in Hauppauge, N.Y.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment